Close Menu

multiple myeloma

Skyline will collaborate with Janssen to develop a test to identify patients at increased risk of side effects from a multiple myeloma drug.

Recent collaboration agreements between the company and researchers at the Moffitt Cancer Center and the Buck Institute for Research on Aging will further its "intention of building a portfolio of oncology-related assays using selected-reaction monitoring," said an official.

The work will focus on the development of mass spec assays for measuring signaling and repair pathway proteins for clinical tumor biopsy analysis.

The company plans two new versions of its MyPRS test later this year, including a pharmacogenomic enhancement called MyPRS RX and a version called MyPRS Plus that will perform myeloma subgroup analysis.

"It may be possible to use available drugs on the shelf that are effective in melanoma to treat myeloma patients with similar mutations," said Kenneth Anderson, the program director and chief of hematologic neoplasias at the Dana-Farber Cancer Institute, adding that he envisions a "very rapid bench-to-bedside translation."

Based on their whole-genome or exome analyses of multiple myeloma samples from 38 individuals, members of the Multiple Myeloma Research Consortium have learned more about known pathways contributing to the disease and identified several previously unidentified genetic players.

Caris will exclusively offer Signal's Myeloma Prognostic Risk Signature, or MyPRS, test to community-based hematologists and medical oncologists across the US.

Signal will use its genomic testing platform in a multiple myeloma research program being conducted by Array BioPharma.

Pages

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.